Identity of Respondent |
59 |
|
Patient
|
45
|
76%
|
18 years or older
|
31
|
53%
|
17 years or younger
|
14
|
24%
|
Parent/Guardian
|
14
|
24%
|
Spouse
|
0
|
0%
|
Patient’s Gender |
56 |
|
Male |
31 |
55% |
Female |
25 |
45% |
Non-binary |
0 |
0% |
Transgender female |
0 |
0% |
Transgender male |
0 |
0% |
Other |
0 |
0% |
Prefer not to say |
0 |
0% |
Patient’s Race/Ethnicity† |
52 |
|
White |
51 |
98% |
Other |
2 |
4% |
American Indian/Alaska Native |
1 |
2% |
Black/African American |
1 |
2% |
Asian |
0 |
0% |
Hispanic/Latinx |
0 |
0% |
Native Hawaiian/Pacific Islander |
0 |
0% |
CFTR Modulator |
53 |
|
Ivacaftor |
2 |
4% |
Lumacaftor/Ivacaftor |
1 |
2% |
Tezacaftor/Ivacaftor |
2 |
4% |
Elexacaftor/Tezacaftor/Ivacaftor |
38 |
72% |
None of these |
10 |
19% |
|
Median |
IQR |
Patient’s Age, N = 56 |
20 |
[13.5 – 30.0] |
‡FEV1 % Predicted, N = 28 |
90 |
[76.0 – 110.5] |